ODT’s Most-Read Stories This Week—July 22

The usual suspects drove ODT website traffic this past week: personnel, product innovation, and a product recall.

Surprisingly, however, the most popular items were all from the prior week. Leading the charge was CurvaFix’s dual announcement of new CEO Mark Foster (former president/chief executive of Trice Medical) and $39 million in equity financing (led by MVM Partners and assisted by Sectoral Asset Management and other investors). 

Aziyo Biologics fueled pageviews with the voluntary recall of its bone matrix products. The company initiated the recall after learning of post-surgical mycobacterium tuberculosis infections in two patients treated with viable bone matrix product from a single donor lot. 

restor3d enticed cybervisitors via its first all-metal patient specific instrument (PSI) in ankle arthroplasty, which could very likely bolster growth of the ankle replacement market, according to GlobalData. 

News of a breakthrough in bionic hand technology also piqued ODT loyalists’ interest. Specifically, visitors zeroed in on a study in Science Translational Medicine that presented the first documented case of an individual whose body was surgically modified to incorporate implanted sensors and a skeletal implant. A.I. algorithms then translated the user’s intentions into movement of the prosthesis. The article shows that rewiring nerves to different muscle targets in a distributed and concurrent manner is not only possible but also conducive to improved prosthetic control.

1. CurvaFix Names New CEO, Closes $39M in Series C

2. Aziyo Biologics Issues Voluntary Recall of Viable Bone Matrix Products

3. restor3D’s All-Metal PSI to Boost Growth in Ankle Replacement Market  

4. Meeting the Challenges of the Medical Device Industry With Compact Manufacturing Innovation

5. Breakthrough: Bionic Hand Allows Finger Manipulation Just Like a Natural Limb